Siete pronte a fare la differenza? Domani, dalle 9:30 alle 16:30, vi invitiamo al nostro stand virtuale in occasione dell'evento #StemGirls Un'intera giornata dedicata alle donne del mondo STEM, con un intervento speciale di Simona Scartoni, Global Biostatistics and Data Management Director. Accedi al link per registrarti: jobmeeting.it/stemgirls #WomenInStem #University #WeAreMenarini
MENARINI Group
Fabbricazione di prodotti farmaceutici
Firenze, Italy 342.165 follower
Chi siamo
The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group
- Sito Web
-
https://www.menarini.com
Link esterno per MENARINI Group
- Settore
- Fabbricazione di prodotti farmaceutici
- Dimensioni dell’azienda
- Oltre 10.001 dipendenti
- Sede principale
- Firenze, Italy
- Tipo
- Società privata non quotata
- Settori di competenza
- ALLERGOLOGY, ANDROLOGY, ANTINFECTIVE AREA, CARDIOVASCULAR AREAS, GASTROINTESTINAL DISORDERS, GYNECOLOGY AND WOMEN'S WELLNESS, PAIN, TRAUMA AND HEADACHES, RESPIRATORY AREA, REUMATOLOGY, FLU, COUGHS AND COLDS, DERMATOLOGY AND PERSONAL CARE, FOOD SUPPLEMENTS, ONCOLOGY e DIAGNOSTICS
Località
-
Principale
Via dei Sette Santi 1/3
Firenze, Italy 50131, IT
-
Dipendenti presso MENARINI Group
Aggiornamenti
-
Asthma is a chronic lung disease that can affect people of all ages, caused by inflammation and muscle tightening around the airways, making breathing more difficult. Typical symptoms can include coughing, shortness of breath, and chest tightness. Other common symptoms include wheezing and a whistling sound in the chest. Discover in our Blog what is an asthma attack and the significant impact on a person’s quality of life 👉 https://lnkd.in/d9yg4Phq #Menarini #Asthma #MenariniBlog
-
Menarini will be present at the 60th Annual Meeting of the European Association for the Study of Diabetes, EASD 2024 from September 9th to 13th in Madrid, Spain. Visit us at booth E.09 With an exceptional scientific programme that extensively covers scientific research, current treatments, technologies and care, the EASD Annual Meeting provides the perfect setting to exchange ideas and network with peers from all over the world, connecting the global diabetes community, sharing groundbreaking diabetes science and research, and offering educational opportunities. We look forward to seeing you in Madrid #Menarinigroup #EASD2024 #MenariniCardiometabolics #T2D #Diabetes #Cardiometabolicdiseases
-
We’re excited to announce Menarini Group's presence in Vienna at the European Respiratory Society (ERS) Congress 2024 from 7th to 11th September. Discover the latest innovations in respiratory care, cutting-edge AI solutions and sustainable practices. Meet the experts and engage in thought-provoking discussions. Visit our booth at B5.01 to learn more! See you there! Join us in Vienna: #ERS2024 #MesseWien #RespiratoryHealth #Innovation #Sustainability #AI #MenariniGroup
-
Today, on World Leukemia Day, we stand with the blood cancer community to raise awareness of this type of blood cancer that affects millions of lives around the world. #WorldLeukemiaDay
-
This September, we join the global community in raising awareness for blood cancer, the fifth most common type of cancer in the world. At Menarini Stemline we are committed to improving the lives of those impacted by #bloodcancer. #BloodCancerAwarenessMonth
-
Menarini will be present at the next ESC Congress 2024, hosted by the European Society of Cardiology, which will take place from August 30th to September 2nd in London, UK. Visit us at booth N° E200. The ESC Congress serves as a catalyst for shaping the future of cardiovascular medicine on a global scale. Looking forward to seeing you in London! #Menarini #Cardiometabolics #ESC2024 #CardiovascularDiseases
-
Jet lag is a temporary sleep disorder caused by rapid crossing multiple time zones, especially on intercontinental flights. There are some remedies to help you with the symptoms. To discover more, read our latest article on the blog 👉https://lnkd.in/dKxjCdhN #Menarini #JetLag
-
The Menarini Group is proud to have sponsored the HTAi Symposium "Embracing patient perspectives in health technology assessments: Integrating Quality of Life, Patient Experience and Preferences" and have contributed to the discussion on the importance of patient involvement for meaningful decision-making in healthcare. A big thanks from the Menarini Group to all the speakers Renate Haidinger, Meindert Boysen PharmD MSc, Neil Bertelsen and Mihai Iulian Rotaru, moderator Jorge Mestre-Ferrandiz and Health Technology Assessment international (HTAi). #menarini https://lnkd.in/dhki3g_G
-
Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Hetegrozyous Familial Hypercholesterolemia. Elcin Barker Ergun, Chief Executive Officer of the Menarini Group: “Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. Despite the widespread availability of lipid lowering therapies, CVD-related deaths have risen and patients remain above LDL-C targets. Patients and their doctors need additional options. We are very pleased that BROOKLYN confirmed the ability of obicetrapib to significantly reduce LDL-C in a challenging patient population, over a duration of one year. This represents an important milestone in our commitment to offer the HeFH community in Europe a potential first in class, oral CETP-i in the fight against cardiovascular diseases, a mission of over 30 years for our company". https://lnkd.in/dxD7qmMj #menarini #cardiovascular